The LY6H and GRM3 proteins could serve as potential biomarkers of glioma-related epilepsy (GRE), according to a study. Among…
Lindsey Shapiro, PhD
Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Lindsey Shapiro, PhD
Adding the investigational therapy LAM561 to standard of care treatment may delay disease progression or death in people with newly…
Tumors in children with aggressive gliomas that formed in the spinal cord all exhibited genetic changes that might be…
GYNECOLOGICAL CANCER
Swollen lymph node leads to fallopian tube cancer diagnosis
In a rare case, a woman in China was found to have fallopian tube cancer in her left tube that…
The U.S. Food and Drug Administration (FDA) has agreed to a priority review of a Chimerix application seeking accelerated…
Researchers in Brazil have developed a large dataset of cells taken from the bone marrow of people with multiple…
The European Commission has approved Blincyto (blinatumomab) as part of a consolidation therapy regimen to reduce the risk of…
GYNECOLOGICAL CANCER
Sempervirine stops ovarian cancer cell growth in preclinical studies
Sempervirine, a compound isolated from a plant used in traditional Chinese medicine, inhibited the growth, spread, and development of…
Regulators in the European Union (EU) have approved Sarclisa (isatuximab) in combination with standard-of-care medications for adults newly diagnosed…
PANCREATIC CANCER
MEK inhibitor IMM-1-104 shows promise in pancreatic cancer: Data
Investigational oral therapy IMM-1-104 was well tolerated and showed early signs of efficacy as a first- or second-line treatment for…